Signifier® Medical Technologies Wins IDEA Design Award 2020 for eXciteOSA®, the World’s First, Daytime Treatment Device That Tackles the Root Cause of Sleep-Disordered Breathing

London, United Kingdom

September 17, 2020

Signifier® Medical Technologies, an innovator in the sleep-disordered breathing market is delighted to announce that it has been awarded a bronze IDEA award by the prestigious Industrial Designers Society of America (IDSA) in the “Medical & Health” category, for its novel medical device, eXciteOSA® – designed for patients with sleep-disordered breathing conditions.

Founded in 1965, Industrial Designers Society of America is one of the oldest and largest industrial design associations in existence, with 2020 marking the 40th anniversary of the International Design Excellence Awards (IDEA).

Originally founded to recognize exceptional achievement in industrial design, the program has since grown with thousands of entries submitted by design teams across the globe, making IDEA one of the largest and most widely anticipated annual awards programs in the world.

Professor Dr Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham, was keenly aware of the fact that many of his patients were struggling with conventional treatment options for their sleep-disordered breathing (SDB) conditions. Based on an understanding of this significant unmet need and working with a talented multidisciplinary team, he created the world’s first, daytime treatment device that tackles the root cause of SDB.

eXciteOSA® works by improving tongue muscle endurance and responsiveness preventing upper airway collapse during sleep. Clinically significant results have been observed, when used for 20 minutes, once a day, for 6 weeks. 2-4

More information about the eXciteOSA IDSA award can be found here: https://www.idsa.org/awards/idea/medical-health/snoozeal

Images of the eXciteOSA® device are available upon request to info@signifiermedical.com

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.1

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.2-4

About International Designers Society of America

Founded in 1965, IDSA is one of the oldest and largest membership associations for industrial design professionals with thousands of members in Student Chapters, Professional Chapters and Special Interest Sections in the United States and internationally. IDSA sponsors IDEA®, the world’s most prestigious and rigorous design competition. The Society hosts events including an annual International Design Conference, five District Design Conferences and a Medical Design Conference, bringing together some of the biggest names and brightest minds in industrial design and related fields.

References

  1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
  2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
  3. Sama A, et al. Daytime Intraoral Neurostimulation with eXciteOSA® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
  4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today

Signifier® Medical Technologies Hosted a Global Webinar on: “Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea”

sleep apnoea

LONDON, 3rd September 2020

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, recently hosted a global webinar with leading world experts in the field of sleep disordered breathing (SDB).

The webinar was centred on “Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea” and it was hosted by Prof. Dr. Adrian Williams (Professor of Sleep Medicine & Consultant Respiratory Physician, a founding member of the Sleep Section of the Royal Society of Medicine) and Prof. Dr. Atul Malhotra, (Research Chief in Pulmonary, Critical Care and Sleep Medicine at UC San Diego, USA).

Prof. Dr. Anshul Sama (Consultant ENT and Sleep Physician at Nottingham University Hospital, UK and inventor of the daytime intraoral neuromuscular electrical stimulation (NMES) technology1-2 for reduction of sleep disordered breathing) also participated in the webinar presenting the technology and the new therapy options provided by NMES.

The webinar shed light on the SDB space, current treatment modalities, and presented the mechanism of action and clinical data on the new NMES technology.

eXciteOSA® is a non-invasive daytime therapy for the tongue which delivers small contractions that improves muscle function and reduces the physiological collapse of the tongue during sleep. The device is a one size fits all and effective when used for 20 minutes a day for six weeks, with sustained improvement with minimal weekly maintenance.

Patients often find conventional night-time solutions for SDB ineffective or difficult to tolerate. With increasing public awareness of sleep related issues, and sleep therapy devices, it is increasingly likely that more patients will be consulting their healthcare professional on the therapy options available to them.

eXciteOSA® gives healthcare professionals and patients an effective therapy that is easy and convenient to use.

If you missed it live, visit www.exciteosa.com/past-webinars to view previous webinars on-demand and register for future webinars.

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy can be limited, so there is a demand for new and innovative approaches.

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.1-3

References

  1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
  2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
  3. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today

Signifier® Medical Technologies to host webinar on Precision Medicine and Non-Invasive therapies for Mild Obstructive Sleep Apnea

Live Webinar: 1st September 7-8pm BST

sleep apnoea

LONDON, 30th July 2020

Signifier Medical Technologies today announced that it will host a live webinar on Monday 1st September 7-8pm BST to learn about the latest advances in the management of sleep disordered breathing and emerging new technologies in the field of sleep medicine.

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

The webinar will feature three experts on sleep disordered breathing, Prof. Dr. Adrian Williams, Professor of Sleep Medicine & Consultant Respiratory Physician, a founding member of the Sleep Section of the Royal Society of Medicine, as well as having been awarded the UK’s first Chair in Sleep Medicine, and Prof. Dr. Atul Malhotra – Research Chief in Pulmonary, critical care and sleep medicine at UC San Diego. He is Peter C. Farrell Presidential chair and Professor in Respiratory Medicine at UCSD. They will be joined by Prof. Dr. Anshul Sama Consultant Rhinologist, Dept. of Neurosurgery, Nottingham University Hospital and inventor of daytime NMES for OSA.

The speakers will cover the following topics in this free webinar:
• Mild Obstructive Sleep Apnea: burden of disease and the need for bespoke management
• Emerging technologies and future trends in management of OSA

The webinar will include a Q&A session with the speakers. Please register HERE.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as Snoozeal®, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.

Signifier’s proprietary therapy is the first and only day time genioglossal muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients. 1-3

References

  1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
  2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
  3. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today

Signifier® Medical Technologies Hosted a Global Webinar on: “Latest Advances in the Management of Sleep Disordered Breathing”

sleep apnoea

LONDON, 17th July 2020

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, recently hosted a global webinar with leading world experts in the field of sleep disordered breathing (SDB).

The webinar was centred on “Precision medicine for obstructive sleep apnea and emerging technologies” and it was hosted by Prof. Dr. Peter Cistulli (ResMed Chair in Sleep Medicine at the University of Sydney, Australia) and Prof. Dr. Atul Malhotra, (Research Chief in Pulmonary, Critical Care and Sleep Medicine at UC San Diego, USA).

Prof. Dr. Anshul Sama (Consultant ENT and Sleep Physician at Nottingham University Hospital, UK and inventor of the daytime intraoral neuromuscular electrical stimulation (NMES) technology1-2 for reduction of sleep disordered breathing) also participated to the webinar presenting the eXciteOSA® technology and the new treatment proposed with the eXciteOSA® device.

The webinar shed new light on the SDB space and presented novel clinical data on the new NMES technology associated with eXciteOSA®.

This new data brought together results from a multi-centre clinical study held in tier-1 academic centres at London Teaching Hospital and Spain (University of Navarra) – with c. 115 participants.

The clinical results showed:

  • Significant clinical reductions in objective mild Obstructive Sleep Apnea (OSA) indexes, including AHI, ODI and RDI; and
  • Subjective questionnaires completed by bed partners that reported a substantial reduction in snoring.

This treatment resulted in an improved quality of sleep for both the patients and their partner3.

eXciteOSA® is a non-invasive daytime therapy for the tongue which delivers small contractions that improves muscle function and reduces the physiological collapse of the tongue during sleep. The device is a one size fits all and effective when used for 20 minutes a day for six weeks, with sustained improvement with minimal weekly maintenance.

Patients often find conventional night-time solutions ineffective or difficult to tolerate. With the increasing public and digital awareness of sleep and sleep devices, it is increasingly likely that more patients will be consulting their healthcare professionals on these issues.

eXciteOSA® gives healthcare professionals and patients an effective solution that is easy and convenient to use.

If you missed it live, visit www.exciteosa.com/past-webinars to view previous webinars on-demand and register for future webinars.

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a demand for new forms of treatment.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as Snoozeal, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients.1-3

References

  1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
  2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
  3. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

Take your first steps towards a restful night’s sleep today